Navigation Links
Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved
Date:3/4/2009

STOCKHOLM, March 4 /PRNewswire-FirstCall/ -- Diamyd Medical announces today that the Swedish Medical Products Agency has approved a study with the Diamyd(R) diabetes vaccine in children with high risk to develop type 1 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"To vaccinate children against diabetes has from the outset been one of Diamyd Medical's long term goals," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Type 1 diabetes is a life-long and very serious disease and it is good if we now can prevent it. It would avoid a lot of anxiety, suffering and costs for the children and their families as well as the rest of Society."

At Malmo University Hospital in Sweden, large screening tests results in a continuous identification of children that are subject to a very high risk of developing type 1 diabetes. By measuring different biomarkers in blood samples, it is possible to determine in an early stage that these children are in the autoimmune disease process that destroys their insulin producing cells.

If vaccination with Diamyd(R) succeeds to intervene in the disease process before too many of the insulin cells are destroyed, the disease will be prevented. The child would then escape diabetes symptoms and would not become dependent on insulin injections for survival, which otherwise is unavoidable.

"We meet with these kids every third month and we know that virtually all of them will present with type 1 diabetes. Many of us pediatricians have been frustrated not to be able to interfere. But now, and I have to admit it feels almost a bit unreal, we may for the first time have a real opportunity to save these children from the disease," says Helena Elding Larsson, pediatrician from Malmo and researcher at Lund University in Sweden.

The approved study comprises, under the present approval, up to 50 children from 4 years of age who are known to have a high risk of developing type 1 diabetes. The study will be randomized and placebo controlled.

This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.

    Diamyd Medical AB (publ.)
    Linnegatan 89 B, SE-115 23 Stockholm, Sweden
    Phone: +46-8-661-00-26,
    Fax: +46-8-661-63-68
    E-mail: info@diamyd.com.

   http://www.diamyd.com


    VATno: SE556530-142001.

    http://www.omxnordicexchange.com ticker: DIAM B;
    http://www.otcqx.com ticker: DMYDY)



'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Diamyd(R) Study Published in Prestigious New England Journal of Medicine
2. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
3. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
4. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
5. Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
6. Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds
7. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
8. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
9. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
10. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
11. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Vascular Ltd., together with its subsidiaries (the "Company" ... the "Group"), is pleased to provide an update ... (now owned by Spectranetics Corporation (NASDAQ: SPNC ... Court of Appeals for the Federal ... court order (the "DCO").   The DCO had dismissed ...
(Date:2/10/2016)... och PITTSBURGH , 10 ... inte, och detta pressmeddelande får inte distribueras, ... till, och inga anmälningssedlar kommer att accepteras ... något land där Erbjudandet, distribution av detta ... skulle strida mot tillämpliga lagar eller regler ...
(Date:2/10/2016)... -- --> --> ... Spectroscopy Market by Industry (Oil & Gas, Petrochemical, Pharmaceutical, Water ... & Mining, and Others), And Geography - Global Forecast ... expected to grow to USD 3.9 Billion by 2020, ... 2020. Browse 82 market data Tables and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance ... program created to assist the people of their local community. The agency pledges ... and community leaders. Their hope is to bring awareness to important local causes ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... Village Family Practice , will be presenting at the 2016 HIMSS Annual Conference ... Nev. , During his session, “ Coding for Care: Using Data Analytics ...
(Date:2/11/2016)... ... 2016 , ... The annual list showcases the 20 Most Promising SharePoint Solution ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members of ... to recognize and promote technology entrepreneurship. , The survey was made at the ...
(Date:2/11/2016)... ... February 11, 2016 , ... From March ... Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center in ... for both the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food ... engaged in health and wellness best practices in the past couple of decades, ... February is American Heart Month, which acts as an exceptional opportunity to revise ...
Breaking Medicine News(10 mins):